Medical capability
Is a named doctor responsible? Is biology measured? Is treatment supervised? Are results checked?
NumiNova Longevity
Building the standard that longevity travel lacks.
A clinic, residential programme and luxury hotel can all sell longevity. NumiNova is building the market intelligence, standards and adviser capability needed to distinguish what each provider actually does and support better decisions for wealthy families.
The problem
The word longevity does not tell a family what it is buying.
A medically governed clinic, a doctor-led residential programme and a luxury hotel with a wellness menu can all use the same word. They do not carry the same clinical responsibility, measurement, treatment or follow-up.
There is no independent global facility standard that makes those differences visible. Families and advisers are left to compare marketing claims. Credible providers are left competing against claims that have not been tested.
- 01
Who holds medical responsibility
- 02
What is measured
- 03
What treatment is provided
- 04
Whether results are checked
- 05
What happens after the stay
What we are building
NumiNova will make the differences visible.
The NumiNova Atlas provides a connected view of the market. The Index will compare provider capability and the strength of the evidence behind it. Certification will recognise providers that meet the relevant standard. Trained advisers will use the results with families.
The standard will describe what a provider has. It will not promise a medical outcome, and no provider, investor or Group company will be able to buy a better result.
Understand the market
Connect providers, programmes, people, capabilities, suppliers and places in one market view.
Define the standard
Set standards that reflect the different roles providers perform.
Compare capability
Use the Index to show what is present and the strength of the evidence behind it.
Recognise providers
Certify providers that meet the standard relevant to the role they perform.
Support decisions
Give trained advisers a better basis for comparing providers with wealthy families.
A decision based on evidence
Longevity travel in practice
A longevity stay is not one booking.
A family may be assessed close to home, travel for treatment, recover elsewhere and continue with its own doctors afterwards. Each provider needs the right records, a defined role and a clear handover to the next one.
01
Set the medical baseline
Complete the appropriate diagnostics and medical review. Record what the next provider needs to know.
02
Choose the right facility
Compare clinical capability, programme design, setting and fit with the family’s requirements.
03
Prepare records and travel
Confirm the programme, accommodation, travel and transfer of relevant records before arrival.
04
Plan recovery
Arrange the recovery setting, follow-up appointments and any specialists required after treatment.
05
Return to continuing care
Give the family’s doctors and advisers the information needed for the next decision.
The NumiNova Atlas
Atlas gives NumiNova a connected view of the longevity market.
It brings providers, programmes, people, capabilities, suppliers and places into one body of intelligence. That understanding helps NumiNova set relevant standards, choose partners, support advisers and identify businesses worth investing in or acquiring.
Explore the NumiNova Atlas- 01
Where credible capability sits
- 02
Which providers perform similar roles
- 03
Which specialists and businesses can work together
- 04
Where important gaps remain
- 05
Which providers may be suited to partnership
- 06
Which businesses may warrant investment or acquisition
Provider assessment
A grade must answer two questions.
What is actually present? How thoroughly has it been checked? Keeping those answers separate prevents a polished website or a paid assessment from being mistaken for medical capability.
Programme capability
Are the method, staff, safety, suitability and follow-up appropriate to the programme being sold?
Supporting capability
Can the place, travel asset or specialist partner perform the role it claims within the wider programme?
The criteria change with the provider. The obligation to support every claim does not.
NumiNova Group
We will buy capability where ownership matters, and partner where it does not.
The Atlas, Index and rulebook must remain NumiNova owned. Facility relationships, assessor capacity and specialist operating expertise may come through acquisitions or partnerships.
We are interested in established teams that bring facility relationships, assessment capability, clinical expertise or a proven route to wealthy families and their advisers.
- Partner
- Work with medical societies, laboratories, regulators, research groups and specialist providers where independence matters.
- Acquire
- Buy owner-led companies with facility relationships, assessor teams or operating expertise that would take years to build.
- Build
- Develop the Atlas, Index, governance and adviser curriculum that must carry NumiNova’s authority.
NumiNova Longevity
Leadership
Amy Stewart leads NumiNova Longevity. Niel Malan and Kalene Smalberger lead the Group capabilities supporting acquisitions, technology, finance and operations.
Amy Stewart
Chief Executive Officer, NumiNova Longevity
Amy has spent nearly two decades building and operating healthcare businesses across medical groups, health technology and wellness. She leads the company’s standard, partnerships, commercial strategy and operating build.
Niel Malan
Founder and Chief Executive, NumiNova Group
Niel founded NumiNova and leads Group strategy, acquisitions, research and technology. He is building the programmatic M&A capability that Longevity will use to acquire specialist companies.
Kalene Smalberger
Cofounder, Operations and Finance, NumiNova Group
Kalene is a Chartered Accountant whose career began at PwC. She leads Group operations and finance, including the controls required as the acquisition programme develops.
Work with NumiNova Longevity.
Contact us if you own a relevant business, operate a facility, work in clinical or standards development, advise wealthy families, can contribute capital or want to help build the company.